MPS disease, short for mucopolysaccharidosis, is a group of rare inherited metabolic disorders in which the body lacks specific enzymes needed to break down complex sugar molecules called glycosaminoglycans (GAGs). Without these enzymes, GAGs build up inside cells over time, gradually damaging tissues and organs throughout the body. There are seven recognized types of MPS, each caused by a different missing enzyme, and the combined prevalence across all types ranges from roughly 1 to 5 per 100,000 live births in most countries.
How MPS Disease Works
Every cell in your body contains tiny compartments called lysosomes, which act like recycling centers. Lysosomes use enzymes to break down worn-out molecules so the parts can be reused. In MPS, one of these enzymes is missing or not working properly, so GAGs pile up inside lysosomes instead of being broken down.
At first, this accumulation is reversible and causes only mild disruption. But as GAGs continue to build, they interfere with how cells manage waste, generate energy, and communicate. The buildup triggers inflammation and oxidative stress, and over months and years, it leads to permanent damage in bones, joints, the heart, airways, liver, spleen, eyes, and in some types, the brain. This progressive nature is why early detection matters so much.
The Seven Types of MPS
Each type of MPS is defined by which enzyme is missing and which GAGs accumulate as a result. Some types have subtypes based on severity or the specific enzyme variant involved.
- MPS I (Hurler syndrome) is further divided into three subtypes ranging from severe (Hurler) to mild (Scheie). It involves buildup of dermatan sulfate and heparan sulfate.
- MPS II (Hunter syndrome) is the only X-linked form, meaning it primarily affects boys. It has a severe neuropathic form and a milder non-neuropathic form.
- MPS III (Sanfilippo syndrome) has four subtypes (A through D), each lacking a different enzyme. It predominantly affects the brain and nervous system.
- MPS IV (Morquio syndrome) comes in two subtypes (A and B) and primarily causes severe skeletal abnormalities.
- MPS VI (Maroteaux-Lamy syndrome) resembles MPS I in many physical features but does not affect intelligence.
- MPS VII (Sly syndrome) is one of the rarest forms and can range from very severe to relatively mild.
- MPS IX (Natowicz syndrome) is extremely rare, with only a handful of cases ever reported. It causes soft tissue masses and joint problems.
There is no MPS V or MPS VIII. MPS V was reclassified as a mild form of MPS I (Scheie syndrome), and MPS VIII was later removed from the classification system.
Common Symptoms Across Types
Most children with MPS appear healthy at birth. Symptoms typically emerge in the first few years of life and worsen over time. While the specific pattern varies by type, many MPS types share overlapping features: coarse facial features that become more pronounced with age, a short trunk and limbs, stiff or swollen joints, an enlarged liver and spleen, clouding of the corneas, frequent ear infections, and heart valve problems.
Skeletal problems are especially common. The bones may grow abnormally, leading to a condition sometimes called dysostosis multiplex, which shows up on X-rays as irregularly shaped vertebrae, thickened ribs, and underdeveloped hip joints. Many children develop a curved spine and have difficulty with fine motor tasks because of stiff fingers and hands.
Airway obstruction is a serious concern in several MPS types. GAG buildup thickens the tissues of the throat and windpipe, and an enlarged tongue can make breathing difficult, particularly during sleep.
Which Types Affect the Brain
Not all MPS types cause cognitive decline, and this distinction is one of the most important for families to understand. MPS I (severe Hurler form), MPS II (neuropathic form), MPS III (all subtypes), and MPS VII can all involve progressive damage to the central nervous system. Children with these forms may develop normally for the first few years, then gradually lose speech, motor skills, and the ability to perform daily activities.
MPS III, Sanfilippo syndrome, stands out because its most prominent feature is neurological. Children often show behavioral problems, sleep disturbances, and hyperactivity before the more visible physical signs of MPS become obvious, which can delay diagnosis.
In contrast, MPS IV (Morquio), MPS VI (Maroteaux-Lamy), and MPS IX (Natowicz) generally spare intelligence. People with these types face significant physical challenges but retain their cognitive abilities. The milder forms of MPS I and the non-neuropathic form of MPS II also preserve cognition, though physical symptoms still progress.
Life Expectancy
Life expectancy varies widely depending on the type and severity. In severe MPS I (Hurler syndrome), children who do not receive treatment often do not survive past the first decade. For the neuropathic form of MPS II (Hunter syndrome), life expectancy is typically 10 to 20 years, with developmental regression beginning between ages 6 and 8. People with the non-neuropathic form of MPS II generally live into adulthood.
Heart disease and airway obstruction are the leading causes of death across most MPS types. GAG buildup stiffens heart valves and narrows airways over time, and these complications often determine how long a person lives even when the brain is unaffected. Milder forms of MPS I, IV, and VI can allow survival into the twenties, thirties, or beyond, particularly with modern treatments.
How MPS Is Diagnosed
Diagnosis typically follows a three-step process. The first step is a urine test that measures the total level and specific types of GAGs being excreted. Elevated or abnormal GAG patterns raise suspicion for MPS but cannot pinpoint the exact type on their own.
The second step is an enzyme activity test, usually performed on a blood sample. By measuring the activity of specific lysosomal enzymes, doctors can identify which one is deficient and determine the MPS type. The third step is genetic testing, which confirms the diagnosis by identifying the specific gene mutation responsible. This is particularly important for carrier testing in family members and for guiding treatment decisions.
Newborn screening is increasingly available for some types. MPS I was added to the U.S. Recommended Uniform Screening Panel (RUSP) several years ago, and in 2022, MPS II was also added. Not all states have implemented screening for both types yet, but the trend is toward earlier detection, which can significantly improve outcomes by allowing treatment to begin before irreversible damage occurs. One important caveat: newborn screening sometimes flags “pseudodeficiencies,” where enzyme levels are low but the child does not actually have MPS, so abnormal screening results always require follow-up GAG and genetic testing before a diagnosis is confirmed.
Treatment Options
Two primary treatments exist for MPS: enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). They work through fundamentally different approaches.
Enzyme replacement therapy delivers a lab-made version of the missing enzyme through regular intravenous infusions, typically once a week or every two weeks. The U.S. Food and Drug Administration has approved ERT for MPS I, MPS II, and MPS VI. ERT can reduce organ enlargement, improve breathing and walking ability, and slow the progression of joint and soft tissue disease. Its major limitation is that the infused enzyme does not cross into the brain effectively, so it cannot prevent or reverse neurological decline in the types that affect cognition.
Stem cell transplantation takes a different approach. Donor stem cells engraft in the patient’s bone marrow and produce the missing enzyme continuously from within the body. Because some of these cells can migrate into the brain, HSCT has the potential to slow or prevent neurological damage, which is why it remains the preferred treatment for severe MPS I (Hurler syndrome) when performed early, ideally before age two. In one study of 42 children with various MPS types who underwent HSCT, over 95% achieved full donor cell engraftment and all reached normal enzyme levels. The estimated one-year survival rate was about 93%, with cord blood transplants showing particularly strong outcomes.
HSCT carries significant risks, including graft failure and complications from the intensive conditioning chemotherapy required beforehand. It works best when a well-matched donor is available and when performed before extensive organ damage has occurred. For MPS IV and VI, experience with transplantation is more limited, and ERT remains the standard first-line approach.
How Common MPS Is
MPS is rare by any measure, but prevalence varies significantly by region. In the United States, the combined rate across all types is approximately 1.2 per 100,000 live births. European countries like the Netherlands and Portugal report higher rates, around 4.5 to 4.8 per 100,000. Saudi Arabia has the highest documented frequency at nearly 17 per 100,000, largely attributed to higher rates of consanguineous (related-parent) marriages.
Among individual types, MPS I and MPS II tend to be the most commonly diagnosed in most populations. MPS I rates range from about 0.34 per 100,000 live births in the U.S. to 1.85 in Norway. MPS III (Sanfilippo) is also relatively common among MPS types, while MPS VII and MPS IX are the rarest, with MPS IX having only a handful of documented cases worldwide. All types except MPS II follow autosomal recessive inheritance, meaning both parents must carry the gene mutation for a child to be affected. MPS II is X-linked recessive, which is why it occurs almost exclusively in boys.